Drug Risk
FDA Approves Boxed Warning About Increased Risk of Blood Clots and Death with Higher Dose of Xeljanz
U.S. Food & Drug Administration
PR-M07-19-NI-074Jul 29, 2019
Marketing Authorization
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis
Pfizer
PR-M08-18-NI-024Aug 07, 2018